KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Invested Capital (2016 - 2025)

Teva Pharmaceutical Industries' Invested Capital history spans 17 years, with the latest figure at $9.7 billion for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 35.87% year-over-year to $9.7 billion, compared with a TTM value of $9.7 billion through Dec 2025, up 35.87%, and an annual FY2025 reading of $9.7 billion, up 35.87% over the prior year.
  • Invested Capital for Q4 2025 was $9.7 billion at Teva Pharmaceutical Industries, up from $7.3 billion in the prior quarter.
  • The five-year high for Invested Capital was $14.8 billion in Q2 2021, with the low at $6.7 billion in Q1 2025.
  • Average Invested Capital over 5 years is $10.3 billion, with a median of $9.8 billion recorded in 2023.
  • Biggest YoY gain for Invested Capital was 35.87% in 2025; the steepest drop was 36.9% in 2025.
  • Tracing TEVA's Invested Capital over 5 years: stood at $12.7 billion in 2021, then decreased by 15.49% to $10.7 billion in 2022, then dropped by 8.49% to $9.8 billion in 2023, then dropped by 26.91% to $7.2 billion in 2024, then soared by 35.87% to $9.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Invested Capital are $9.7 billion (Q4 2025), $7.3 billion (Q3 2025), and $7.3 billion (Q2 2025).